OR Royalties Inc. (NYSE:OR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

OR Royalties Inc. (NYSE:OR) has earned an average rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $38.25.

Several research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of OR Royalties in a report on Monday, December 29th. Raymond James Financial upgraded OR Royalties from a “market perform” rating to an “outperform” rating and set a $41.00 target price for the company in a research report on Thursday, November 6th. Wall Street Zen raised OR Royalties from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. Jefferies Financial Group restated a “hold” rating and issued a $38.00 price target on shares of OR Royalties in a research note on Sunday, December 7th. Finally, Canaccord Genuity Group upgraded shares of OR Royalties from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 22nd.

Hedge Funds Weigh In On OR Royalties

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OR. Linden Thomas Advisory Services LLC grew its holdings in OR Royalties by 4.1% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 6,254 shares of the basic materials company’s stock valued at $221,000 after buying an additional 249 shares in the last quarter. Cetera Investment Advisers increased its position in OR Royalties by 3.5% in the second quarter. Cetera Investment Advisers now owns 13,147 shares of the basic materials company’s stock worth $337,000 after purchasing an additional 440 shares during the last quarter. Vident Advisory LLC raised its stake in OR Royalties by 2.0% during the second quarter. Vident Advisory LLC now owns 42,349 shares of the basic materials company’s stock valued at $1,089,000 after purchasing an additional 820 shares in the last quarter. Assetmark Inc. bought a new position in OR Royalties during the fourth quarter valued at $36,000. Finally, PFG Investments LLC grew its stake in shares of OR Royalties by 4.1% in the 4th quarter. PFG Investments LLC now owns 25,992 shares of the basic materials company’s stock worth $920,000 after buying an additional 1,030 shares in the last quarter. 68.52% of the stock is owned by institutional investors.

OR Royalties Trading Down 13.7%

Shares of NYSE:OR opened at $39.46 on Friday. The stock has a 50 day moving average of $37.84 and a 200 day moving average of $34.83. The company has a market cap of $7.38 billion, a PE ratio of 49.95 and a beta of 0.78. OR Royalties has a 12-month low of $17.55 and a 12-month high of $47.75.

OR Royalties (NYSE:OR) last issued its quarterly earnings results on Wednesday, November 5th. The basic materials company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.03. The business had revenue of $71.63 million for the quarter, compared to the consensus estimate of $53.85 million. OR Royalties had a net margin of 60.72% and a return on equity of 10.67%. Equities research analysts predict that OR Royalties will post 0.62 earnings per share for the current fiscal year.

OR Royalties Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Wednesday, December 31st were issued a dividend of $0.055 per share. This represents a $0.22 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, December 31st. OR Royalties’s dividend payout ratio is 27.85%.

About OR Royalties

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.